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Abstract 
 
Raf Kinase Inhibitor Protein (RKIP) has been identified as a 
phosphatidylethanolamine-binding protein capable of inhibiting Raf-1 
kinase, an enzyme significant in cell proliferation and cancer 
development.  When properly functioning, RKIP can mediate the 
expression of Raf-1 kinase and help prevent uncontrolled cell division.  
RKIP also has suggested, but unclear, roles in spindle fiber formation during 
mitosis, regulation of apoptosis, and cell motility. The Fenteany laboratory 
in the Chemistry Department identified a new small molecule, named 
Locostatin, as a cell migration inhibitor in mammalian cells, with RKIP as its 
primary molecular target.   
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Dictyostelium discoideum possess two RKIP proteins, RKIP-A and 
RKIP-B.  In order to begin to study the function of RKIP in D. discoideum 
and its role in cell motility, I created a mutant cell line which lacks a 
functional RKIP-A gene.  In this paper, we show that removal of RKIP-A 
does not affect vegetative motility, but impairs chemotaxis and 
development in the presence of drug.  Interestingly, RKIP-A knockout 
mutants appear more resistant to drug effects on vegetative motility than 
wild-type cells.  More research is needed to reconcile these seemingly 
contrasting results, and to better develop a model for RKIP-A’s role in cell 
motility. 
 
 
 
Introduction      
 
The ability of eukaryotic cells to crawl on surfaces is a highly 
regulated and crucial component of life. During development, embryonic 
cells migrate long distances to organize into tissues. Immune cells are 
perpetually moving through adult tissues searching for abnormal cells and 
moving to sites of trauma and inflammation.  Motility, though necessary to 
sustain life, possesses negative aspects as well, including the ability of 
cancer cells to leave solid tumors and metastasize to new locations (1). 
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The actin cytoskeleton is the dominant participant in cell motility. The 
polymerization of new actin filaments at the front of the cell drives 
extension of membrane in the direction of movement, while the 
contraction of the filament network by myosin pulls along the back of the 
cell. Cells that have been genetically engineered to lack cytoskeletal 
proteins often have reduced or absent motility (2), and certain drugs and 
toxins can also cause cells to lose the ability to move (3).  Due to motility’s 
importance to the maintenance of life, research regarding its 
mechanisms, as well as its regulation, is of critical importance. 
The cytoskeleton is composed of protein groups known as 
microfilaments, microtubules, and intermediate filaments (4).  The 
microfilaments, which are predominantly actin filaments, however, are 
the principal forces driving cell migration.  Actin exists in cells in two 
distinct forms: globular monomeric actin (G-actin) and linear polarized 
filaments (F-actin) which assemble by polymerization of G-actin.  These 
filaments possess a “plus” and “minus” end, and although both ends are 
capable of undergoing this elongation, monomers add much more 
readily to the plus end than the minus end (5).  The force of this actin 
polymerization near the plasma membrane results in a membrane 
protrusion as the growing filament ends push on the membrane.  
Protrusion is defined as the extension of the front of the cell in direction of 
movement and necessitates cell adhesion to a surface.  Following 
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protrusion, the rear of the cell must detach from the surface and be 
retracted into the cell body by myosin molecular motors, resulting in cell 
movement.  Protrusion can be accomplished in the form of filopodia, thin 
and narrow extensions of the membrane, or lamellipodia, thin and broad, 
ruffled extensions of the membrane.  In filopodia, actin is organized in 
bundles parallel to the axis of protrusion.  In the case of lamellipodia, actin 
filaments are arranged in perpendicular arrays, in a grid that is generally 
about 45° to the direction of movement (6).  Amoeboid cells present 
protrusions as pseudopods, which are similar to filopods, but are 
considerably thicker.  In all cases, research has shown that the extension 
of the membrane is a result of actin polymerizing at the leading edge of 
this projection, and the basis for cellular migration (6).  While actin is 
known to be necessary to motility, other proteins and complexes have 
been implicated in helping to assist actin nucleation and polymerization, 
and in promoting cell migration (7).  Research is currently under way to 
determine these potential secondary facilitators of cell motility.  One of 
the ways to accomplish this task is to identify cell migration inhibiting 
compounds and then work to identify their targets. 
 Research studying inhibitors of cell migration is of particular interest, 
as the inhibitors may be able to be developed into therapeutics to 
prevent cancer cell metastasis or tumor angiogenesis.  Dr. Gabriel 
Fenteany, of the UConn Chemistry Department, has conducted a high 
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throughput screen to identify cell migration inhibitors.  In this screen, a 
monolayer of Madin-Darby Canine Kidney cells is given a scratch wound, 
and then the cells are treated with a compound to determine if the 
wound healing is affected.  This screen is quite useful, as it is both rapid, 
and relatively specific because wound-healing involves cell migration 
much more than cell division, thereby essentially removing the effect of 
cell proliferation.  The Fenteany lab screened a library of compounds, and 
from this screen an oxazolidinone derived compound was identified as a 
novel inhibitor of cell motility.  This compound is not toxic at the 
concentrations used to cause cell motility to cease, and the effects are 
reversible when the compound is washed from the cells.  Furthermore, this 
compound is not found to be toxic to Gram-negative or Gram-positive 
bacterial cells (1).  This oxazolidinone derivative was termed “Locostatin”, 
to identify it as a compound capable of inhibiting cellular motility in a 
number of model systems (8). 
 A crucial aspect of drug discovery is identifying the target of a 
particular compound.  Identification allows the compounds to be 
modified and improved, and the mechanism of action to be studied.  To 
determine the role Locostatin plays in cellular biochemistry, radioactively 
labeled Locostatin was synthesized and introduced to small amounts of 
MDCK cell extract.  Locostatin was found to covalently bind four cytosolic 
proteins from these cells: Raf Kinase Inhibitor Protein (RKIP), glutathione S-
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transferase, aldehyde dehydrogenase, and prolyl oligopeptidase. 
Locostatin analogs were found to bind to RKIP as well, with an increased 
binding correlated to greater decreases in cell migration.  This result and 
the fact that the other potential targets are considered “housekeeping 
enzymes” related to metabolism leads to the conclusion that RKIP is the 
most likely target related to motility defects.  Some of these analogs, 
which have high levels of toxicity, do not bind well to RKIP, and the 
conclusion can be drawn that RKIP inactivation is not necessarily coupled 
with cell death.  To further confirm RKIP as a target of the drug, RNAi was 
used to reduce the amount of RKIP in the cell, which resulted in less 
migratory MDCK cells, reminiscent of the drug’s effect on cell motility.  
Conversely, over-expression of RKIP makes cells less sensitive to the drug, 
indicating that more drug is needed to induce the same effect on motility 
(8).   
 Locostatin has been shown to covalently bind RKIP in a way that 
makes it unable to bind Raf-1, which is hypothesized to be one of RKIP’s 
primary targets.  RKIP, a member of the phosphatidylethanolamine 
binding protein family (9), exists in the cytoplasm as a small, globular 
protein with a ligand binding pocket, and it has been suggested that it is 
in this pocket that the protein binds Raf-1 kinase (10).  In binding Raf-1 
kinase, unphosphorylated RKIP inhibits Raf-1’s kinase activity and thereby 
inhibits the mitogen-activated protein kinase (or MAPK) cascade.  RKIP 
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inactivation allows for the return of the kinase activity and the Raf-1 
initiated phosphorylations (11). 
The MAPK cascade is a complex signaling pathway inducing cell 
division, development, and differentiation.  It has been suggested that 
growth factors are responsible for activating kinases, which then proceed 
through a phosphorylation cascade.   The signal is amplified through the 
pathway, until it reaches regulatory molecules in the cytoplasm or nucleus 
that then direct the cell to enter a certain cellular process, such as cell 
division.  The most-researched component of the MAPK cascade is the 
protein Raf-1.  Upon stimulation by interaction with the protein RAS, Protein 
Kinase C (PKC), as well as other unknown supplementary activators, Raf-1 
phosphorylates MEK, which then phosphorylates ERK-1 and ERK-2.  These 
downstream kinases perpetuate the cascade and have been shown to 
induce cellular proliferation.  If control is lost, however, this pathway 
frequently leads to oncogenesis (11). 
Recent research suggests that RKIP binds Raf-1 in a way which 
competitively disrupts Raf-1’s association with MEK and ERK (11).  It has 
also been suggested that RKIP may bind MEK-1 in addition to Raf-1, and 
that binding may also induce suppression of the MAPK cascade (12).  If 
RKIP is phosphorylated at serine 153 by PKC, RKIP no longer binds Raf-1, 
but instead binds G-protein-coupled-receptor 2 (GRK2), a highly 
important negative feedback regulator of G-protein coupled receptors 
 11 
(GPCRs), and blocks the phosphorylation of other GPCRs (12-16).  
Interestingly, the lack of RKIP does not appear to stimulate the MAPK 
cascade.  In contrast, it appears that RKIP is a mediator of this cascade, 
and that in its absence, cells are particularly vulnerable to stimuli, such as 
epidermal growth factor (10).  In this way, RKIP appears to buffer cells from 
environmental stimuli, and when lacking, make the cells much more 
sensitive and vulnerable, but it is not loss of RKIP, itself, that stimulates such 
biochemical responses (10). 
 RKIP is also implicated as a critical player in spindle fiber formation 
during mitosis.  A loss of RKIP, and a resulting increase of unbound Raf-1, 
increases the rate of cell proliferation.  Raf-1 is a major factor influencing 
the rate of cell division, and without RKIP to mediate its function, cells 
show increased, and more haphazard, division.  Research suggests that a 
decrease in RKIP results in a reduction of mitotic index, due to a hasty 
entry into anaphase.  This hurried entrance into anaphase has been 
shown to result in inappropriate chromosome segregation, leading to 
aneuploidy, and general chromosomal volatility (17).  This role for RKIP is 
one of the reasons why the RKIP gene has been identified as a metastasis 
suppressor gene (MSG) (18).  Loss of RKIP has now been found in 
numerous types of cancer including prostate cancer, breast cancer, and 
melanoma (10), as well as ovarian cancer (19), and colorectal cancer 
(20).  RKIP does not appear to affect tumor growth, but does seem to act 
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to suppress overall cell invasiveness by inactivating MEK.  For example, in 
mice with prostate cancer, over-expression of RKIP has been found to 
reduce cancer metastasis to the lungs by 70% and reduce angiogenesis 
in their existing tumors (14, 18). 
 Recently, research has also shown RKIP to be a key regulator of 
apoptosis, or programmed cell death.  It is thought that RKIP is up-
regulated in cells that are exposed to drugs that induce DNA damage 
and apoptosis, as occurs during chemotherapy.  RKIP has been shown to 
also exert control over the nuclear factor kappa-B (NF-κB) pathway, and 
this is now thought to be the foundation for RKIP’s role in cell death.  NF-κB 
is a transcription factor involved in the immune response, which protects 
cell from apoptosis; in contrast, RKIP’s inhibition of this pathway seemingly 
allows potentially oncogenic cells to become vulnerable to apoptotic 
death (15, 21).  A rapid increase in RKIP production has been observed in 
breast and prostate cancer cells at the onset of apoptosis from drug-
induced DNA damage, leading to the conclusion that RKIP sensitizes cells 
to apoptotic death.  This is corroborated by the knowledge that RKIP 
inhibits both the NF-κB and MAPK cascade pathways, and the findings 
that inhibition of either pathway makes cells more vulnerable to apoptosis.  
Furthermore, breast and prostate cancer cells have been shown to have 
greatly-reduced levels of cellular RKIP, but when RKIP is re-expressed in 
breast cancer cells, they undergo spontaneous apoptosis (21).  As a result, 
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it has been suggested that cancer cells down-regulate RKIP to increase 
their chances of survival and to augment their ability to metastasize (9, 
21).   
RKIP down-regulation has been cited as a principal reason why 
prostate cancer cells are resistant to death from radiation therapy.  In 
contrast to chemotherapy-treated cells, the cells do not up-regulate RKIP 
upon the onset of radiotherapy-induced apoptosis; instead, it has been 
found that a loss of RKIP inhibits apoptosis in radiation-treated cells and 
allows for further cell proliferation.  This research suggests that patients 
suffering from cancers that result in intrinsic loss of RKIP expression would 
be better treated with surgery or chemotherapy than with radiation 
therapy (22).  Furthermore, prostate cancer primary tumors expressing low 
levels of RKIP had a 40% greater chance of recurrence, indicating that loss 
of RKIP expression may be used as a prognostic marker for prostate 
cancer, and other cancers with reduced RKIP expression in primary tumors 
and metastases (20, 23, 24). 
 In addition to RKIP’s critical roles in cell proliferation, apoptosis, 
metastasis, and cell migration pathways, RKIP has been identified as a 
precursor of the hippocampal cholinergic neurostimulating peptide 
(HCNP) (important in hippocampal and myelin sheath development, and 
acetylcholine synthesis (15)), a serine protease inhibitor, a protein involved 
in sperm membrane synthesis during spermatogenesis, and as a possible 
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contributor to the development of Alzheimer’s Disease and Diabetes (14, 
15, 25).  There is no doubt that for all these reasons, RKIP is not only a 
protein critically important to cellular function, but one also worthy of 
careful study, as the gene shows promise to be modified therapeutically, 
or at the very least, to shed more light upon disease development and 
potential prevention. 
 My research uses Dictyostelium discoideum cells as a model system 
to study the role of RKIP in cell motility and cell function. D. discoideum, a 
hearty soil amoebae, is an excellent model system not only because 
genetic manipulation of the haploid cells is well established, but also 
because the behavior of wild-type cells is well-characterized.  In addition, 
these cells behave similarly to macrophages and neutrophils, immune 
cells which function to combat illness as well as neoplastic disease, 
making D. discoideum research findings that much more significant.  I 
found that Locostatin inhibits cell motility in D. discoideum as well as in 
mammalian cells, without cytotoxicity. Analysis of the D. discoideum 
genome revealed two RKIP homologs, RKIP-A and RKIP-B, which are the 
likely targets of the drug and highly similar to mammalian RKIP proteins. 
The presence of RKIP in both D. discoideum and mammalian cells 
emphasizes RKIP’s importance, as it is a protein that has been conserved 
during a long evolutionary timespan. 
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 In order to study the function of RKIP in D. discoideum, I created a 
mutant cell line which lacks a functional RKIP-A gene.  This cell line 
allowed me to study the effect of RKIP-A’s removal on cell motility and the 
effect of Locostatin on these cells. Because the Cre-loxP system was used, 
additional gene disruptions can be made to this same cell line, which will 
be useful in the development of a double RKIP-A and RKIP-B knockout.  
Because the RKIP proteins in D. discoideum contain many regions highly 
similar to RKIP in other cell lines, any information obtained from the gene’s 
removal will benefit the study of the way this protein functions in many cell 
lines and model systems.  A greater understanding of the function of this 
protein will ideally lend itself to the development of RKIP-related cancer 
treatments, perhaps including direct modification of the RKIP gene as an 
anti-cancer therapy. 
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Methods  
 
Cell Culture  
 Dictyostelium discoideum, strain AX2, were grown in HL-5 media (10 
g BBL Thiotone E Peptone, 10 g glucose, 5 g yeast extract, 0.35 g 
Na2HPO4·7H2O, 0.35 g KH2PO4, in 1000 ml water, pH 6.5-6.7, and 
autoclaved for sterility) at 21°C and passaged approximately every four 
days, upon reaching confluency.  Cells were provided by the Knecht lab. 
 Escherichia Coli, strain DH5α, were grown on SM/Ampicillin agar 
plates and then inoculated into 2 ml LB (10 g Bacto-tryptone, 5 g yeast 
extract, 10 g NaCl, in 1000 ml water, pH 7.5, and autoclaved for sterility) 
broth in glass capped tubes.  Tubes were placed on a shaker in 37°C 
room and allowed to grow overnight.  Cells were provided by the Knecht 
Lab. 
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 Klebsiella aerogenes were inoculated into a flask of LB broth and 
grown, stationery on a lab bench, at room temperature, and then plated 
and grown on SM plates.  Cells were provided by Charito Romeo. 
 
Construction of Targeting Vector for Gene Knockout (26) 
 The targeting vector was made by cloning RKIP 5’ and 3’ flanking 
regions of approximate 1000 base pairs onto the sides of a Bsr cassette in 
the pLPBLP Cre-lox vector.  The flanking regions were amplified by 
Polymerase Chain Reaction.  The PCR products and plasmid were 
digested with restriction endonucleases and used in ligation reactions.  
Bacterial cells were transformed by heat-shock, colonies were picked and 
mini-prepped, and the resulting DNA was single digested and visualized 
on an agarose gel to look for a shift in size and the presence of an 
insertion.   
 The 3’ flanking region incorporated itself into the pLPBLP vector, 
while the 5’ flanking region did not.  Therefore, the 5’ flanking region was 
introduced to the Bluescript PKS- vector for blue/white screening.  White 
colonies were picked, and screened for the insertion.  The DNA of a 
positive colony was digested with the appropriate restriction enzymes to 
remove the 5’ fragment, and that fragment was used in ligation reactions 
with the pLPBLP vector plus 3’ fragment.  Again, colonies were screened 
for the second insertion.  Positive colonies were then subjected to 
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numerous diagnostic restriction digests to ensure proper vector 
construction.   
 
DNA Isolation 
 Wild-type Dictyostelium DNA isolation for PCR reactions of 5’ and 3’ 
flanking regions was performed by DNAzol treatment.  A confluent plate 
of approximately 107 wild-type cells was harvested and centrifuged at 483 
x g for five minutes.  Cells were washed in MCPB , resuspended in 1 ml 
DNAzol reagent, transferred to an Eppendorf tube, and inverted until the 
solution became clear.  The tubes were centrifuged, and the supernatant 
was transferred to a new tube, and mixed with 100% ethanol to 
precipitate DNA.  The prep was centrifuged in a microfuge at 13,000g for 
10 minutes.  The supernatant was removed and the DNA pellet was 
washed and spun twice in 70% ethanol.  The DNA was then resuspended 
in 200 ul of 8mM NaOH and stored at -20°C. 
 DNA isolation from bacterial cultures for screening for proper DNA 
construction was performed through alkaline lysis mini-preps.  1 ml of 
bacterial culture was transferred from glass capped tubes to 1.5 ml 
Eppendorf tubes.  Cells were pelleted in a microcentrifuge at 13,000 rpm 
for 2 minutes.  Cells were resuspended in 200 ul of Buffer I (50 mM Tris-HCl, 
10 mM EDTA, pH 8.0).  Then, 200 ul of Buffer II (1% SDS, 0.2 M NaOH) were 
added to the tubes, and the tubes were mixed by inverting five times.  
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Tubes were let incubate at room temperature for five minutes.  After five 
minutes, 200 ul of Buffer III (3.0 M Potassium Acetate, pH 5.5 with Glacial 
Acetic Acid) were added to the tubes and mixed by inversion five times.  
Tubes were allowed to incubate at room temperature for five minutes and 
were then centrifuged in a microfuge at 16060 x g for ten minutes.  After 
spinning, the supernatants were transferred to clean Eppendorf tubes, 
taking care not to remove any precipitate with it.  1 ml of 100% ethanol 
was added to the tubes, which were mixed by inversion, and allowed to 
incubate at room temperature for two minutes.  The tubes were then 
centrifuged at 13,000g for 15 minutes.  When the centrifuging was 
complete, supernatants were removed and DNA pellets were washed in 
500 µl of 70% ethanol, and centrifuged for an additional 5 minutes.  
Supernatants were removed and tubes were stood open and inverted to 
allow residual ethanol to evaporate.  The DNA pellet was resuspended in 
20 µl of TE (10 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0) containing 20 ug/ml 
RNase A.  Three microliters of these samples were run on agarose gels to 
ensure presence of plasmid. 
 Targeting vector isolation from bacterial cultures for use in 
electroporation was performed with a Qiagen Plasmid Midi-prep kit, using 
a vacuum manifold. 
 DNA isolation for PCR screens of mutants was performed through 
whole-cell PCR preparations (27).  Transformed cells, grown in 1 ml HL-5 
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media in 24-well plates to confluency, were harvested, and 1 ml of 
suspended cells was placed in 1.5 ml Eppendorf tubes.  Cells were 
pelleted in a microcentrifuge at 13,000 rpm for 1 minute.  Media was 
aspirated and cells resuspended in 25 ul distilled water.  100 ul of Lysis 
Buffer (10 mM Tris base pH 8.3, 50 mM KCl, 2.5 mM MgCl2, 0.45% NP-40, 
0.45% Tween) was added to the tubes, followed by 4 ul of 20 ug/ml 
Proteinase K in distilled water.  Tubes were mixed by pipetting, and were 
then placed at 95°C for one minute to inactivate the Proteinase K.  DNA 
preps were immediately ready for PCR reactions, in which 1 ul of DNA was 
used, and remaining DNA was stored at 4°C. 
  
Polymerase Chain Reaction 
 RKIP 5’ and 3’ flanking regions were amplified with two sets of 
oligonucleotides in Hot-Start PCR reactions, as seen in Table 1.  Four tubes 
of each reaction were prepared to combine in later gel extractions.  
When the PC R had ended, the tubes were pooled, and phenol and 
chloroform extraction was performed to remove the polymerase, before 
the samples were loaded on a gel.  All PCR reactions were performed in a 
PTC-100 Programmable Thermal Controller. 
 
Table 1. – Hot Start PCR Reactions 
5’ Flanking Region PCR Reaction 3’ Flanking Region PCR Reaction 
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Ingredients Ingredients 
3 ul wild-type DNA 3 ul wild-type DNA 
2 ul mM dNTPs 2 ul mM dNTPs 
2 ul 10x Denville Hot Start Taq Buffer 2 ul 10x Denville Hot Start Taq Buffer 
2 ul P1F primer 2 ul P2F primer 
2 ul P1R primer  2 ul P2R primer 
6.3 ul sterile ddH20 6.3 ul sterile ddH20 
1 ul Denville Hot Start Taq 1 ul Denville Hot Start Taq 
Program: I. 94°C -5 minutes, II. 94°C – 45 seconds, III. 55°C – 45 seconds, IV. 
72°C – 2 minutes,  
V. 40x to II, VI. 72°C – 5 min. 
 
                RKIP mutants were screened in multiple PCR screens using 
primers specific to the RKIP coding region, the Blasticidin-resistance 
cassette, and genes adjacent to RKIP flanking regions, as seen in Table 2.   
 
Table 2. – PCR Screen Reactions 
External PCR 
Screen 
Internal 
Coding PCR 
Screen 1 
Internal 
Coding PCR 
Screen 2 
Internal Bsr 
PCR Screen 1 
Internal Bsr 
PCR Screen 2 
1 ul sample 
DNA 
1 ul sample 
DNA 
1 ul sample 
DNA 
1 ul sample 
DNA 
1 ul sample 
DNA 
4 ul 5x HF 
Phusion 
Buffer 
4 ul 5x HF 
Phusion 
Buffer 
4 ul 5x HF 
Phusion 
Buffer 
4 ul 5x HF 
Phusion 
Buffer 
4 ul 5x HF 
Phusion 
Buffer 
2 ul 2mM 
dNTPs 
2 ul 2mM 
dNTPs 
2 ul 2mM 
dNTPs 
2 ul 2mM 
dNTPs 
2 ul 2mM 
dNTPs 
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1 ul ER primer 
1 ul CR1 
primer 
1 ul CF2 
primer 
1 ul IR primer 1 ul IF primer 
1 ul EF primer 1 ul EF primer 1 ul ER primer 1 ul EF primer 1 ul ER primer 
0.4 ul 
1mg/ml 
RNase 
0.4 ul 
1mg/ml 
RNase 
0.4 ul 
1mg/ml 
RNase 
0.4 ul 
1mg/ml 
RNase 
0.4 ul 
1mg/ml 
RNase 
10.4 ul sterile 
ddH20 
10.4 ul sterile 
ddH20 
10.4 ul sterile 
ddH20 
10.4 ul sterile 
ddH20 
10.4 ul sterile 
ddH20 
0.2 ul Phusion 
High Fidelity 
Polymerase 
0.2 ul Phusion 
High Fidelity 
Polymerase 
0.2 ul Phusion 
High Fidelity 
Polymerase 
0.2 ul Phusion 
High Fidelity 
Polymerase 
0.2 ul Phusion 
High Fidelity 
Polymerase 
Program: I. 95°C – 30 seconds, II. 58°C – 30 seconds, III. 68°C – 4 minutes, 
IV. 30x to I, V. 68°C – 10 minutes. 
 
 
Agarose Gel Electrophoresis 
                DNA gels were prepared with 1% agarose in 1x TAE buffer (40mM 
Tris acetate, 1mM EDTA, pH 8.0).  30 ml 1x TAE buffer and 0.3 g agarose 
were combined in a flask, microwaved in short intervals to melt the 
agarose, and then allowed to cool slightly while the Bio-Rad Mini-Sub Cell 
GT gel apparatus was assembled.  3ul of 10 mg/ml Ethidium Bromide was 
added to the agarose, and the preparation was then poured into the gel 
apparatus and allowed to solidify for approximately 30 minutes.   
 When the gel had hardened, the comb and wedges were 
removed.  4ul of 1kb DNA ladder preparation (100 ul NEB 1k DNA ladder, 
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100 ul distilled water, and 400 ul 6x gel loading buffer) were pipetted into 
the first well.  6x gel loading buffer was added to each PCR tube to a final 
concentration of 1x and the samples were then loaded onto the gel. 
 The DNA gels were run at 75 volts for approximately 40 minutes, and 
were then viewed on a FotoPrep I ultraviolet light (by Fotodyne). 
 
DNA Extraction from Agarose Gels 
 DNA bands were cut out of the gels with clean razor blades and 
placed in 1.5 ml Eppendorf tubes.  The Qiagen Gel Extraction kit was then 
used to purify the DNA from the gel. 
 
Restriction Digests 
 Restriction digests of PCR products as well as plasmids were 
performed using NEB restriction endonucleases.  Restriction enzymes used 
for the RKIP 5’ flanking region were KpnI and HindIII, while restriction 
enzymes used for the RKIP 3’ flanking region were PstI and BamHI. 
Reactions were prepared with approximately 1 ug of PCR product or 
plasmid DNA, 5 ul of the proper 10x NEBuffer (Buffer 2 for KpnI and HindIII, 
Buffer 3 for BamHI and PstI), 1 ul 10 mg/ml BSA, 1 ul each restriction 
enzyme, and distilled water to a total reaction volume of 50 ul.  Reactions 
were incubated at 37°C for one hour, and phenol and chloroform 
extraction was used to remove the enzymes.  
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Ligation Reactions 
 Ligation reactions were designed with a 1:3 molar ratio of vector to 
insert.  In a total volume of 20 ul, the appropriate amount of insert and 
vector were added, as well as 2 ul NEB 10x Buffer for T4 DNA Ligase and 1 
ul T4 DNA Ligase.  The reactions were incubated for one hour at room 
temperature, and 10 ul of the solution were used in heat-shock bacterial 
transformation. 
 
Transformation of Cells 
 Bacterial cells were transformed by heat-shock.  DH5α cells, stored 
at -80°C, were thawed on ice.  50 ul of bacterial cells were mixed with 10 
ul of the ligation reaction mix and were incubated on ice for 30 minutes.  
Tubes were then immediately transferred to the glass bead bath in the 
37°C room for 40 seconds, and then were promptly put back on ice for 2 
minutes.  Then, 100 ul of LB broth were added to the tubes and this mix 
was spread onto LB-Ampicillin plates and placed at 37°C overnight, so 
that colonies could be picked the next day.  When performing blue/white 
selection, 40 ul of 2% X-gal in DMSO was spread on the plates and 
allowed to dry 30 minutes at 37°C before transformation.  The following 
day, white colonies were selected. 
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 The targeting vector was isolated from midi-prepped E. Coli and 
was digested with KpnI and BamHI in a sequential restriction digest to 
remove the constructed portion of DNA.   
 1x107 wild-type D. discoideum cells were harvested and pelleted at 
4°C.  Cells were washed twice in ice-cold H-50 buffer (20mM HEPES, 50mM 
KCl, 10mM NaCl, 1mM MgSO4, 5mM NaHCO3, 1mM NaH2PO4, pH 7.0), 
resuspended in 50 ul ice-cold H-50, and kept on ice for the remainder of 
this procedure.  5 ug of midi-prepped and digested plasmid DNA were 
added to the cell suspension.  Oligonucleotides homologous to the ends 
of the targeting DNA were added to the cells and DNA suspension at a 
final concentration of 100 uM.  Cells and DNA were transferred to sterile, 
ice-cold 0.1 cm electroporation cuvettes.  Cuvettes were pulsed twice in 
a BTX ECM 630 Electroporator at 0.6kV/50uF/25 Ohms, and then were 
incubated on ice for an additional 5 minutes; cells were then moved to 10 
ml dishes of HL-5. 
 
Selecting Transformants 
 After electroporation, cells are allowed to heal overnight in HL-5 
media.  The next day, fresh HL-5 media was added, and 5 ul of 10mg/ml 
Blasticidin was added to the dish, and incorporated by swirling. 
 In intervals of three days, the dish was swirled to remove dead cells 
from the plate surface, the media was aspirated and changed, and new 
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Blasticidin was added.  After 10-12 days, surviving cells were harvested.  
300 ul K. aerogenes were placed in an Eppendorf tube, and 100 
transformed D. discoideum cells were added (requiring dilution from the 
original tube of harvested cells).  Another tube of K. aerogenes was 
prepared with 1000 transformed cells.  Cells were plated with a sterile 
spreader onto SM agar plates.  Cells were allowed to grow for 5-7 days, 
and when plaques were clearly visible, they were scraped with a sterile 
pipette tip and cells were introduced into 1 ml HL-5 media in a 24-well 
dish.  These cells were allowed to grow to confluency for whole cell DNA 
prep, and subsequent PCR screens.  
 
SDS-PAGE and Western Blot Analysis 
 Western blots were used to compare protein expression levels of 
RKIP mutants.  All cells were grown in 100mm polystyrene Falcon plates.  
Cells were harvested in mid-log phase, at a density of approximately 2x106 
cells/ml, pelleted, and resuspended in 100 ul cold PEE with protease 
inhibitors (0.02M NaPO4 pH 6.8, 2mM EDTA, 2mM EDGA, 20 ug/ml 
Leupeptin, 0.08 mg/ml Aprotinin, 20 ug/ml Pepstatin ).  100 ul 2x SDS Lysis 
Buffer (100 mM Tris-HCl pH 6.8, 200 mM dithiothreitol, 4% SDS, 0.2% 
Bromophenol blue, 20% glycerol) were added to each tube, and the 
tubes were boiled at 95°C for five minutes in a heat block.  Protein 
amounts were quantified in a Bradford Assay. 
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 50 ug of protein from each lysate were loaded onto a 12% SDS gel 
in triplicate.  SDS gels were allowed to run at 120V for approximately 45 
minutes, and then proteins were transferred to Millipore PVDF membrane 
at 12V for 2 hours in transfer buffer (Laemmli Buffer [2.5 mM Tris base pH 
8.3, 192 mM Glycine, 1% SDS, into 1000 ml distilled water] and methanol to 
a final percentage of 20%).  The membrane was blocked in non-fat dry 
milk and PBST (8.0 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4, 0.05% 
Tween-20, into 1000 ml, pH 7.4; 0.5 g non-fat dry milk can be added to 10 
ml PBST to make blocking solution) for 30 minutes.  One of the sets of 
samples was then incubated with 1:666 rabbit-polyclonal anti-human RKIP 
antibody, while another was incubated with 1:1000 rabbit-polyclonal 
filamin antibody (as a control) for an hour.  The gel after transfer, as well as 
the last set of samples, were stained in Coomassie Blue dye (0.2% 
Coomassie blue R250, 10% acetic acid, 25% isopropanol) as a transfer 
control.  Following the primary antibody, the membranes were washed in 
PBST and then incubated in 1:5000 Jackson goat anti-rabbit antibody 
conjugated to alkaline phosphatase.  All antibody dilutions were made in 
PBST.  The membrane was developed in freshly made Development 
Staining Buffer (22.5 ml Development Buffer [12g Tris Base, 095g MgCl2, 
5.85g NaCl in 1000 ml, pH 9.5], 2.5 ml Nitroblue tetrazolium [1 mg/ml in 
Development buffer], and 25 ul 1000x BCIP [50 mg/ml in DMSO]) for 20 
minutes.   
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RT-PCR Analysis  
 Cell samples were plated in wells of a 24-well plate.  250 ul of Trizol 
reagent were added to wells of confluent cells and incubated for 5 
minutes at room temperature.  After incubation, cells were removed from 
surface by tritteration and transfered to an Eppendorf tube.  50 ul of 
chloroform were added to the tube which was then vortexed and 
centrifuged at 12,000g for 15 minutes at 4°C.  The colorless, aqueous 
upper phase was moved to a new tube, 100 ul of Isopropanol were 
added, and the tube was incubated at room temperature for 10 minutes.  
After incubation, the tube was centrifuged at 12,000g for 10 minutes at 
4°C.  The supernatant was removed, and the RNA pellet was washed 
once in ice cold 75% ethanol.  The tube was left open for 15 minutes to 
allow ethanol to evaporate, and then the pellet was solubilized in 20 ul of 
nuclease-free water.  RNA concentration was measured at 260 nm in the 
spectrophotometer and calculated with this equation: 
OD (505 ul / 5 ul) (0.033 ug/ul  / 1OD) = ug/ul RNA 
 cDNA synthesis was performed with a High-Capacity cDNA Reverse 
Transcription Kit from Applied Biosystems.  cDNA was then used in a PCR 
reaction with GFP-R and CF2 primers to determine mRNA signal from wild-
type and mutant cells.   
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Drug and Control Solution Preparation and Storage 
 100 mM Locostatin stock, solubilized in dimethlysulfoxide, was 
obtained from Dr. Fenteany’s lab.  Experimental concentrations of the 
drug were prepared as seen in Table 3 (dilutions were performed after 25 
uM to ensure accuracy). 
 
Table 3. – Experimental Locostatin Preparations 
Final Locostatin 
Concentration 
Volume Locostatin Volume HL-5 Media 
100 uM 
2 ul 100 mM Locostatin 
stock 
1998 ul 
50 uM 
1 ul 100 mM Locostatin 
stock 
1999 ul 
25 uM 
1 ul 100 mM Locostatin 
stock 
3999 ul (only 2000 ul 
used per experiment) 
12.5 uM 
1000 ul 25 uM 
Locostatin preparation 
1000 ul 
6.25 uM 
500 ul 25 uM Locostatin 
preparation 
1500 ul 
  
 Control solutions of DMSO were prepared with equal volumes of 
DMSO as Locostatin per experiment, as seen in Table 4. 
 
Table 4. – Experimental Control DMSO Preparations 
Final Locostatin Volume DMSO in Volume HL-5 Percent DMSO 
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Concentration in 
Experimental 
Treatments 
Corresponding 
Control 
Treatments 
Media in 
Corresponding 
Control 
Treatments 
in 
Corresponding 
Control 
Treatments 
100 uM 2 ul 1998 ul 0.1 % 
50 uM 1 ul 1999 ul 0.05% 
25 uM 1 ul 
3999 ul (only 2000 
ul used per 
experiment) 
0.025% 
12.5 uM 
1000 ul 0.25% 
DMSO 
preparation 
1000 ul 0.0125% 
6.25 uM 
500 ul 0.25% 
DMSO 
preparation 
1500 ul 0.00625% 
 
  
 Locostatin and DMSO stocks were stored at -20°C, while leftover 
experimental preparations were stored at 4°C. 
 
Locostatin Treatment Assays 
 In the first experiments examining Locostatin effect on wildtype 
cells, 1-5 x 105 cells in mid-log phase were added to 2 ml HL-5 media in a 
60 mm polystyrene Falcon plate.  Cells were allowed to attach to the 
surface for one hour.  After one hour, HL-5 media was removed, and HL-
5/DMSO control solution was placed in the dish.  Cells were imaged for 
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one hour.  The HL-5/DMSO solution was then removed, but kept in a 15ml 
conical tube for later use.  The corresponding experimental Locostatin 
preparation was added to the dish, and cells were imaged until they 
appeared round, and were no longer moving.  After the cells had 
rounded up, the Locostatin solution was removed, and the saved HL-
5/DMSO control solution added back to the dish.  Cells were imaged for 
several hours to film recovery from the drug.  This assay was performed 
with 100 uM, 50 uM, 25 uM, 12.5 uM, and 6.25 uM concentrations of 
Locostatin to determine concentration effects. 
 To compare the effect of Locostatin on wildtype and knockout 
mutant cells, 1x105 cells were suspended in 1 ml of HL-5 and plated in 
glass-bottomed Willco dishes.  The appropriate HL-5/DMSO solution was 
added to a well before imaging, cells were imaged for approximately 30 
minutes, and then the HL-5/DMSO solution was removed and replaced 
with a HL-5/Locostatin solution.  Two recovery methods were used.  In one 
assay, drug was washed from cells, and replaced with control media and 
DMSO.  Cells were imaged to recovery.  In the other assay, drug was not 
removed upon ceasing of cell migration; instead, cells were left in drug 
and allowed to recover on their own.  Cells were imaged over a period of 
hours or overnight until new RKIP biosynthesis had rendered the cells 
motile again.   
 32 
 To examine the effect of the drug during starvation, cells were 
plated in the same manner as above, but MCPB was used instead of 
control media.  Cells were allowed to starve for one hour before drug 
addition. 
 
Growth Assay 
 Cells were introduced to 100mm polystyrene dishes with 10ml HL-5 
media or into 30ml HL-5 in 125ml Erlenmeyer flasks at a concentration of 5 
x 104 cells/ml.  Dishes were stored at 21°C and kept stationery, while flasks 
were put on a G10 Gyratory Shaker at room temperature and were 
shaken at 160 rpm.  Cells were counted approximately every 12 hours by 
triturating cells from dishes or drawing cells directly from flasks. 
 
Development Assay  
 Agar plates, made with 1.5% Noble Agar in MCPB, were poured at 
2.5 ml per 60mm dish and allowed to solidify for a few hours.  Cells were 
harvested, centrifuged, washed twice in MCPB, and then 1x107 cells were 
resuspended in 3 ml of MCPB.  Immediately before being added to the 
dish, cells were vortexed to prevent clumping and then were immediately 
poured onto the agar.  Cells were allowed to settle for 15 minutes, and 
then buffer was gently pulled off with a pipette and the agar was dried to 
completion by blotting with a Kimwipe.  Imaging of cells began at 3 hours 
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of starvation and continued for 20 more hours to capture streaming as 
well as fruiting body formation.   
 For development on agar with Locostatin, agar was prepared as 
previously described, and the appropriate volume of drug was added to 
the agar when it had cooled below 50°C. 
 
Chemotaxis Assay  
 SM agar plates were prepared a day in advance by melting 
agarose in SM media to a final concentration of 1.5%.  6 ml were added 
to 60mm polystyrene dishes, and when cooled, three troughs were cut in 
the agar with razor blades.  100ul of wild-type cells at a density of 1 x 107 
cells/ml were added to one outer trough, and 100ul of knockout cells at 
the same density were added to the other outer well.  100ul of 0.1 mM 
folate in SM was added to the middle well.  Cells were allowed to migrate 
out the wells for 4 hours, and then the cell front was imaged near the 
trough edge. 
 For chemotaxis in the presence of drug, Locostatin was added to 
the appropriate concentrations in the agar, cell preparations, and folate 
chemoattractant preparations, so as not to produce a gradient of drug 
as well as folate.  Cells were imaged as above.   
 
Motility Assay 
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 1-5 x 106 cells in mid-log phase were added to 2 ml HL-5 media in a 
60 mm polystyrene Falcon plate.  Cells were allowed to attach to the 
surface for one hour and were then filmed for multiple hours.  Cell motility 
was analyzed using the manual tracking plug-in in the Image J software.   
 
Chemokinesis Assay 
 Cells were grown for at least 3 days in synthetic media (Amino 
acids: 3.3 mM L-Arginine, 2.3 mM L-Asparagine, 1.1 mM L-Aspartic Acid, 
2.5 mM L-Cysteine·HCl, 12.0 mM Glycine, 3.7 mM L-Glutamic Acid, 1.4 mM 
L-Histidine, 4.6 mM L-Isoleucine, 6.9 mM L-Leucine, 8.5 mM L-Lysine·HCl, 2.3 
mM L-Methionine, 3.3 mM L-Phenylalanine, 7.0 mM L-Proline, 4.2 mM L-
Threonine, 1.7 mM L-Tryptophan, 6.0 mM L-Valine; Vitamins: 0.020 mg/L 
Biotin, 0.005 mg/L Cyanocobalamin, 0.200 mg/L Folic Acid, 0.400 mg/L 
Lipoic Acid, 0.500 mg/L Riboflavin, 0.600 mg/L Thiamine·HCl; Phosphate 
Salts: 8.82 mM KH2PO4; Salts: 2.0 mM NaOH, 0.2 mM NaCl, 0.2 mM 
NaHCO3, 1.0 mM NH4Cl, 0.02 mM CaCl2, 0.10 mM FeCl3, 0.40 mM MgCl2; 
Trace Elements: 13 uM Na2EDTA, 1.8 uM H3BO3, 0.7 uM CoCl2, 0.6 uM 
CuSO4, 0.08 uM (NH4)6Mo7O24, 2.6 uM MnCl2, 8 uM ZnSO4; 56 mM Glucose) 
prior to experiment, thereby being exposed to a constant 0.45 uM 
concentration of folate.  Folate was added to aliquots of FM media to 
concentrations of 0.1 mM, 1.0 mM, and 5.0 mM.   
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 In one type of assay, standard FM media was removed from cells, 
and FM with 0.1 mM folate was is added.  Cells were filmed for 60 minutes, 
when the media was removed and FM with 1.0 mM folate was added.  
This proceeded the same way with FM with 5.0 mM folate.  In another 
assay, FM with 5.0 mM folate was added directly to cells that had been in 
FM media, to determine if the chemokinetic effect to folate from the 
previous assay was additive.   
 
 
 
 
 
 
 
 
 
 
Results  
 
Motivation for Project 
 Locostatin was first determined to act as a cell migration inhibitor in 
D. discoideum by treatment of wild-type cells with varying concentrations 
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of the compound.  Cells in control HL-5 media with DMSO concentrations 
comparable to that of the drug preparations were imaged at 10x 
immediately before drug addition.  During this time, cells moved at an 
average of 2.5 um/min.  The HL-5 media with DMSO was then removed 
and a Locostatin preparation was added to the dishes.  When Locostatin 
was added at high concentrations, such as 100uM, cell motility gradually 
decreased until the cells were completely stationary and very round 
(Figure 1A).  When added at low concentrations, such as 25 or 12.5 uM, 
cells became stationary, but often still extended protrusions, or continued 
to move, albeit minimally.  Two means of recovery were observed; if 
100uM Locostatin was removed upon the cells rounding up, cells 
recovered full motility in approximately two hours.  Left in the drug, cells 
would recover full motility in approximately six hours.  These preliminary 
results were the basis for the subsequent project, aimed at trying to 
understand the role of RKIP in cell motility.    
 
The Effect of Locostatin on the Actin Cytoskeleton  
  Dictyostelium wild-type cells expressing GFP-labeled ABD-120 were 
used to examine the effect of Locostatin on the cytoskeleton.  This probe 
localizes to F-actin filaments in cells so it allows monitoring of the state of 
the actin cytoskeleton in these cells, using a Leica confocal microscope.  
Treatment of the cells with 100uM Locostatin produced very surprising 
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results.  These cells do not begin to respond to the drug until about 60 
minutes following drug treatment which is much longer than the data 
reported in Figure 9.  Furthermore, localization of the GFP-probe did not 
seem to change upon drug addition or drug response.  The wild-type 
strain used for this experiment was NC4A2, as opposed to all other 
experiments which used strain AX2 cells.     
 Low-magnification imaging of NC4A2 cells following treatment with 
Locostatin confirms that they are more resistant to the effect of the drug.  
While both cells types round up temporarily upon drug addition, NC4A2 
cells are able to recover their motility much more dramatically than AX2 
cells, which recover minimally and then quickly lose all ability to migrate 
(Figure 1B).   
 
Construction of a Knockout Vector 
 To learn more about the mechanism of the drug, as well as the role 
of RKIP in motility, and the characteristics of an RKIP-A knockout mutant, a 
targeting vector was constructed using a Cre-lox vector and the 5’ and 3’ 
flanking regions of the RKIP gene (Figure 2A).  Amplification of the flanking 
regions was the first problematic component of making the construct, 
and could only be accomplished in hot-start PCR reactions, using Denville 
Hot Start Taq.  Vent DNA Polymerase was unsuccessful at amplifying the 
fragments, and resulted in no amplification or faint DNA smearing.  Hot-
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start Taq corrected this problem by preventing annealing and extension 
at sub-optimal temperatures (Figure 3).  Bands remained faint, however, 
so to increase the yield of DNA, multiple reactions were prepared and 
pooled before being run on an agarose gel. 
Construction of the targeting vector was only successful when 
attempted in a rapid, and thorough, approach.  The first attempts at 
targeting vector construction over the course of many days, or even 
weeks, resulted in a lack of incorporation of flanking regions into the 
vector, as well as anomalous bands upon DNA digestion. Due to the 
suspicion that a slower approach was allowing for exonuclease activity of 
enzymes still present in the DNA samples, all of the steps of PCR, isolation 
and ligation were carried out over a period of two days.  Following all 
procedures involving enzymes, including PCR and restriction digests, a 
phenol and chloroform extraction was performed to inactivate and 
remove the polymerase and endonucleases.  By performing the PCR, 
phenol-chloroform extraction, DNA gel purification, DNA digestion and 
ligation in only one day, the intact 3’ flanking region was successfully 
introduced into the Cre-lox vector (Figure 4A).  The successful construct 
was confirmed by single-digestion (Figure 4B) and double-digestion with 
appropriate restriction enzymes (Figure 4E).  The 5’ flanking region 
remained difficult to incorporate.  To overcome this problem, the 5’ PCR 
product was first cloned into Bluescript.  The PCR product and Bluescript 
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vector were digested with KpnI and HindIII, and ligated.  White colonies 
were picked and screened to confirm insertion of the 5’ flanking region 
(Figure 4C) by single digestion (Figure 4D) and double-digestion (Figure 
4E).  Because the insert was incorporated by ligation of sticky ends and 
not by blunt ligation, it was certain that the ends of the fragment had 
maintained their integrity.  The 5’ region was then digested out of the 
Bluescript vector and ligated into the Cre-lox vector already containing 
the 3’ insert, (Figure 5A) and the ligation product was confirmed by 
double-digestion (Figure 5B).   
  
Transformation of Dictyostelium Cells and Screening for Mutants 
Transformation of D. discoideum with the targeting DNA, purified 
from the plasmid backbone, (Figure 5C) also proved challenging.   Cells 
were transformed on three different occasions, with and without oligos 
homologous to the targeting region, as it has been suggested that a 
greater percentage of transformed cells possess the correct 
recombinations when transformed with oligos.  Transformants were 
selected for resistance to Blasticidin.  The resulting transformants were 
cloned to obtain individual colonies and then screened by PCR for 
knockouts.  Several sets of primers were used to authenticate the removal 
of the RKIP coding sequence, and the presence of the Bsr sequence 
proximal to the RKIP flanking DNA.  In all cases, PCR screens (Figure 2B) 
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showed either no mutants, or unexpected DNA bands.  Even some 
samples which appeared promising were shown by PCR to have single 
rather than double homologous recombinations, or other strange and 
unexpected incorporations of the target DNA into the genome (Figure 6A 
& 6B).   
The third transformation yielded multiple clones that appeared to 
be knockout mutants in initial screens, and one was confirmed by PCR 
(Figure 7A) to have all the expected characteristics of a knockout.  In 
addition, RT-PCR analysis of mRNA isolated from mutant and wild-type 
cells showed the absence of RKIP mRNA in the mutant (Figure 7B).  
Western blotting showed a band at the position of RKIP in both mutant 
and wild-type, however the primary antibody used was rabbit polyclonal 
anti-human RKIP antibody, which may bind RKIP-B as well as RKIP-A.  RKIP-
A and RKIP-B are very similar in size, at 22.1 and 23.7 kilo-daltons, 
respectively, which may cause the cross-reactivity.   
Despite the lack of a confirmatory Western blot, we are confident 
that the mutant is an RKIP-A knockout based upon the PCR screens and 
the definitive RT-PCR results.   
 
Characterization of the RKIP Mutant Phenotype 
Growth 
 41 
A number of assays were used to characterize the phenotype of 
the RKIP-A mutant.  First, the difference in growth rate between wild-type 
and knockout mutants was determined.  Cells were grown in HL-5 growth 
media either in shaking suspension or attached to polystyrene dishes.  
RKIP-A knockout mutants did not have a significantly different growth rate 
from wild-type cells when they were grown attached to a dish with 
generation times of 13.02 ± 0.73 and 11.48 ± 0.62 hours, respectively 
(p=0.066) (Figure 8).   Knockout mutants do, however, differ significantly 
from wild-type cells in growth rate when in shaking suspension (p=0.049).  
Knockout mutants grown in suspension exhibit a generation times of 16.62 
± 0.27 hours, in contrast to wild-type cells’ growth rate of 13.17 ± 1.35 
hours.  The generation time of wild-type cells in dishes is not significantly 
different than the generation time of wild-type cells grown in shaking 
suspension, with respective generation times of 11.48 ± 0.62 and 13.17 ± 
1.35 hours (p=0.370).  In contrast, knockout cells exhibit significantly 
different growth rates in dishes and in shaking suspensions, with respective 
generation times of 13.02 ± 0.73 and 16.62 ± 0.27 hours (p=0.034) (Figure 7).  
Significance was determined using ANOVA: Single Factor tests, and p-
values less that 0.05 were concluded to be significant.   
  
Vegetative Motility 
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Vegetative motility of knockout mutants is morphologically very 
similar to wild-type cells and the cell speed is not significantly different 
between the two (p=0.910).  Knockouts exhibit an average cell speed of 
2.87 ± 0.98 um/min, while wild-type cells exhibit and average cell speed of 
2.92 ± 0.82 um/min.  Cellular morphology also appears very similar 
between the two cell types.  Significance was determined using ANOVA: 
Single Factor tests, and p-values less that 0.05 were concluded to be 
significant.   
 
The Effect of Locostatin on Motility 
 Cells were treated with 100uM and 50uM concentrations of 
Locostatin and imaged to determine the effect of the drug on their 
vegetative random motility.  At a concentration of 100uM, the time it took 
for the drug to have an effect on wild-type and knockout cells is quite 
similar (Figure 9A), while a concentration of 50uM results in substantially 
different reaction times. Wild-type cells exhibit a sharp decrease in cell 
speed only minutes after drug addition and decrease to a speed of 
about 0.5 um/min after approximately 15 minutes.  Knockouts, however, 
exhibit a much more gradual decrease in speed, reaching 0.5 um/min in 
approximately 1.5 hours (Figure 9B).    
Recovery times are also substantially different between the cell 
types.  Treatment of cells with 100µM Locostatin suppresses wild-type 
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motility for approximately 5 hours, at which time cells begin extending 
protrusions and slowly translocating.  In knockout mutants, however, 
recovery begins to occur in approximately 0.5 hours, and, like wild-type, 
motility resumes first by stationary cells extending protrusions, and then 
slowing beginning to migrate again.  This presumably results from the new 
synthesis of RKIP-A until all the drug is bound by the protein.  Conversely, 
preliminary data suggest that knockout mutants may exhibit longer 
recovery times when treated with drug while in MCPB instead of HL-5 
growth medium.  
 
Chemotaxis 
 Wild-type and knockout mutants were also compared during 
under-agarose chemotaxis.  Wild-type cells were placed in one well 
opposite the 0.1mM folate chemoattractant source, while knockout 
mutants were placed in the other adjacent well.  Cells were allowed to 
migrate toward the folate source for four hours and were then imaged.  
Wild-type cells and knockout mutants show no significant difference in 
their cell speed or persistence during chemotaxis toward a folate 
chemoattractant under agar.  Wild-type cells exhibit an average cell 
speed of 3.6 um/min and persistence of 0.88, while knockout mutants 
exhibit an average cell speed of 3.2 um/min and persistence of 0.83.  
When 50uM Locostatin is used, however, wild-type cells are able to 
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migrate out of the well toward the folate chemoattractant approximately 
three hours before knockout cells.  While cell speed does not differ during 
chemotaxis with and without Locostatin, both cell types experience 
reduced persistence, averaging 0.48 for wild-type and 0.52 for knockouts, 
toward the folate source during chemotaxis in the presence of Locostatin. 
  
Development 
The ability of mutant cells to carry out multicellular development 
was also examined (Figure 10).  When starved, Dictyostelium cells begin to 
secrete pulses of cAMP and use this chemical as a chemoattractant to 
aggregate into multicellular mounds.  These mounds then go through a 
series of morphological changes ending up as a fruiting body composed 
of stalk cells supporting a ball of spores.  Knockout cells begin 
aggregation at the same time as wild-type cells, but it takes them much 
longer to accomplish this aspect of development.  By 23 hours, when the 
wild-type has nearly finished development, the mutant is still in the 
aggregation phase.  They never reach the fruiting body stage.   Even after 
30 hours, they only form slugs, which never completely develop, in 
contrast to wild-type cells which develop fruiting bodies in 24 hours.  When 
cells are developed on agar containing 50uM Locostatin, wild-type and 
knockouts exhibit even greater differences.  Wild-type cells develop 
slower than cells developed without drug, and begin to form fruiting 
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bodies at approximately 29 hours after starvation.  Furthermore, wild-type 
cells developed on agar with drug form only about 25% as many fruiting 
bodies as wild-type cells developed on agar without drug.  Knockout cells 
developed on agar with 50uM Locostatin aggregate poorly, stream 
minimally, and remain in disorganized mounds of cells even after 30 hours 
of starvation.   
Discussion 
 
Preliminary Observations 
Effect of Locostatin on Dictyostelium 
 The Fenteany laboratory provided us with a number of compounds 
they had shown to inhibit motility in mammalian cells.  When Locostatin 
was tested in Dictyostelium, the cells also exhibited a rapid inhibition of 
their motility.  Based on these observations that Locostatin inhibited cell 
migration in multiple cell types, including mammalian cells and D. 
discoideum, it was concluded that its target, RKIP, was likely a very 
important protein, conserved through evolutionary time, and worthy of 
study. 
 
Effect of Locostatin on the Actin Cytoskeleton 
 NC4A2 cells containing a GFP-ABD-120 probe were imaged before 
and after drug addition to determine the effect of the drug on the actin 
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cytoskeleton.  Surprisingly, no obvious differences were seen in the probe 
over time.  Furthermore, we were surprised to find that the NC4A2 strain 
cells seemed more resistant to Locostatin than AX2, even though both 
strains are wild-type.  Two possible explanations for this phenomenon exist.  
First, NC4A2 cells are inherently more motile than AX2, and therefore may 
exhibit a greater resistance to motility inhibition by Locostatin.  Secondly, 
GFP-ABD-120 cells possessed somewhat more stable actin and that, too, 
may help buffer the effect of the drug. 
 To study this further, we will image AX2 cells containing the same 
probe to see if there is any noticeable difference between the cell types.  
In addition, we are currently working on making a GFP-RKIP probe, which, 
upon completion, will be introduced to wild-type cells.  Visualizing RKIP 
localization during drug treatment as well as other cellular processes will 
likely shed more light on RKIP’s roles in these processes, as well as the 
mechanism of action of Locostatin. 
 
Construction of the Knockout Vector and Confirmation of the Mutant 
 The making of an RKIP-A knockout mutant was seemingly simple 
until we were confronted with many unexpected obstacles. 
First, it remains unclear why initial attempts at 5’ flanking region 
incorporation into the vector were unsuccessful, while 3’ flanking region 
incorporation was quite easy.  Furthermore, there is no reason that ligation 
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of the fragment into the Bluescript vector should have been any easier 
than ligation into the Cre-lox vector, as they were both digested with the 
same restriction enzymes.  Still, however, by this method, the knockout 
vector was successfully created.  Our results stress the need to work 
rapidly in the construction of a targeting vector to prevent DNA 
degradation, and that simple single and double restriction digests are 
simple and effective methods for determining loss of restriction sites and 
loss of integrity of DNA ends.   
The inability to confirm knockout mutants also prompted 
speculation. At the time, we conjectured that an RKIP-A knockout mutant 
might be lethal, and therefore, the only live mutants observed were non-
homologous or single homologous recombinants.  Discussing these results 
with others in the field, we learned that these unintentional 
recombinations are not as uncommon as we thought. It appears that 
many labs have encountered this puzzling, and potentially misleading, 
problem, but very little is published on the matter (28).  These results 
emphasize the need for thorough PCR screens to confirm genetic 
disruptions in potential mutants. At a minimum, PCR screens to validate 
putative mutants should include an examination of entire gene size, and a 
determination of an insertion into the target DNA, as well as a loss of the 
coding region from the target DNA.   
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Knockouts were finally confirmed by PCR screens, as well as RT-PCR.  
The contradictory Western blot results can be explained by the antibody 
cross-reacting with RKIP-B, as it is a polyclonal antibody, and RKIP-A and 
RKIP-A are very similar in size, differing by only 1.6 kilo-daltons.   
 
Characterization of RKIP Knockout Mutant 
Growth 
 While we were not sure what to expect of the growth rate of 
knockout mutants, knockouts in other model systems have been shown to 
have an increased rate of cell division, due to a reduction in mitotic index 
(17).  It was therefore somewhat surprising to learn that RKIP-A knockout 
mutants grow significantly slower than wild-type cells when being grown in 
shaking suspension.  It is currently unclear why RKIP-A knockout mutants 
exhibit longer generation times than wild-type cells, both in dishes, and in 
shaking suspension, or why cells grown in suspension are so dramatically 
reduced in doubling time.  Still, RKIP-A does appear to have some, 
possibly indirect, role in cell division. 
 
Vegetative Motility 
While we anticipated knockout mutants to have dramatically 
altered motility, we found that wild-type cells and knockout cells do not 
differ significantly in their vegetative migratory ability.  Again, these results 
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were surprising, and in direct contrast to our hypothesis.  One potential 
explanation for this observation is that RKIP-B is able to compensate for 
the loss of RKIP-A, and maintain seemingly normal vegetative cell motility.  
Another possible explanation is that the RKIP interactions underlying cell 
motility are more complicated than we had once thought, and that 
simply removing the gene may not enough an impetus to disrupt 
vegetative motility.  Finally, it is possible that Locostatin’s effect on cells is 
due to the binding of a molecular target other than RKIP, which would 
render these results interesting, but not necessarily informative about the 
way in which Locostatin inhibits motility, and the way that RKIP mediates 
this cellular function. 
 
Effect of Locostatin on Cell Motility 
As RKIP is the molecular target of Locostatin, differences in the 
response of cells to the drug were expected between wild-type cells and 
RKIP-A knockout mutants.  The most anticipated result was that knockout 
mutants would exhibit greater resistance to Locostatin, as they are missing 
the drug’s primary molecular target.  Our results confirm this hypothesis.  At 
high, 100uM, concentrations of Locostatin, the two cell types are quite 
similar in drug response; this is likely because the excess drug is binding 
RKIP as well as targets of lesser affinity, and therefore greatly impairing cell 
migration.  At a lower concentration of 50uM, however, knockout cells 
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respond much slower to Locostatin than do wild-type cells.  We currently 
do not have a model to explain why they still are inhibited, only with a 
greater delay, and will need to examine this phenomenon more closely.   
It would be interesting to find that a change in RKIP expression 
during starvation may lead to phenotypic differences between the cell 
types during drug treatment under conditions of starvation, as preliminary 
data seems to support.  In future experiments, RKIP-A and RKIP-B levels will 
be determined by immunoblotting after different durations of starvation, 
to determine if change in expression of RKIP-A during starvation may 
prompt greater sensitivity or resistance to the Locostatin.  Furthermore, 
motility will be even more closely examined by analyzing amount of 
membrane protrusions of drug-affected cells when treated with varying 
concentrations, especially low concentrations, of the drug. 
 
Chemotaxis 
 Upon discovering that vegetative motility did not differ between 
wild-type cells and knockout mutants, we hypothesized that ability to 
chemotax would also not differ.  Indeed, wild-type and knockout cells do 
not exhibit differences in cell speed or persistence when chemotaxing 
under agarose toward a folate chemoattractant. 
 When chemotaxing in the presence of 50uM Locostatin, however, 
wild-type cells are able to sense the gradient and leave the well 
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approximately three hours before the knockout cells.  Both cells types 
experience approximately a 50% decrease in persistence toward the 
folate source, but no difference in cell speed.  
 While we are currently unsure of its role, these results suggest a role 
for RKIP in the sensing of a gradient, that is inhibited by drug exposure. 
 
Development 
 While we were not sure what to hypothesize about the 
developmental ability of knockout mutants, some research has suggested 
that RKIP is only expressed vegetatively, and therefore, we were not 
expecting to see a dramatic difference in ability of knockout mutants to 
differentiate.  Contrary to this hypothesis, knockout mutants begin 
aggregation at the same time as wild-type cells, but continue to 
aggregate even when the wild-type cells are almost finishing 
development.  Furthermore, knockout mutants never develop fully into 
fruiting bodies, but instead remain in the slug phase even after 30 hours.   
In the presence of 50uM Locostatin, wild-type cells develop fully, 
however the process takes place over approximately 29-30 hours, instead 
of the normal 24 hours.  In contrast, knockout mutants do not even begin 
aggregating until approximately 24 hours, and never progress past this 
point.  Cells remain in disorganized mounds even after 30 hours.  This data 
supports earlier observations that starved knockout mutants are more 
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negatively affected by drug treatment than knockout mutants in growth 
medium.   
First, a chimeric streaming assay will be performed to determine if 
knockout cells, in the presence of wild-type cells, are able to follow the 
lead of properly developing cells, or if they remain deficient in 
developmental ability.  If they remain unable to develop into the fruiting 
body, it may be concluded that RKIP may be involved in the following of 
a gradient, which may help to explain these results, as well as the results 
from chemotaxis in the presence of drug.   
The developmental Western blot previously mentioned will provide 
information in this regard as well, and will help to determine if the 
interactions between and the changes of expression in RKIP-A and RKIP-B 
play a role in the phenotypic differences observed here.  It is clear that 
RKIP plays a role in Dictyostelium development, however, it is unclear what 
that role may be, and further study is needed to elucidate this function 
better. 
 
Final Conclusions 
From these results, a few primary conclusions about RKIP-A emerge: 
the protein is not necessary for cell viability or motility, but does appear to 
have a role in cell differentiation.  Furthermore, loss of RKIP seems to 
confer a greater drug resistance to vegetative cells in growth medium 
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than cells in starvation buffer, however it seems to make knockout 
mutants more sensitive to the drug during chemotaxis and starvation. 
We speculate that RKIP-B may be compensating for the effect of 
losing RKIP-A in the cell or that RKIP-A may have a less critical role in cell 
motility and viability than RKIP-B, and therefore knockout cells are only 
minimally affected.  Furthermore, research suggests that RKIP has a very 
complex and multi-faceted role in cells, and this research seemingly 
confirms that conclusion.  RKIP is likely involved in highly complicated 
signaling pathways, and loss of RKIP-A is seemingly affecting cells in ways 
we do not yet understand.  Due to RKIP’s implication in so many diverse 
cellular processes, it is likely that RKIP-A loss is not only affecting motility, 
but many other cellular functions as well.  This may account for the 
conflicting phenotypes associated with RKIP-A knockout mutants.  A 
double knockout of RKIP-A and RKIP-B will be made to try to elucidate 
these interactions further.  This paper further stresses the need for more 
research on the signaling mechanisms involving RKIP, as its dynamics 
maybe even more complicated than once thought. 
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Figure 2 – DNA Manipulation and PCR Screens 
A) Approximately 1000 base pairs from the 5’ and 3’ flanking regions of the 
RKIP gene were cloned onto the sides of the Bsr cassette, and the target 
DNA was electroporated into wild-type cells.  Knockout mutants were 
produced when double homologous recombination of the target DNA 
disrupted the RKIP gene.  The cells were then selected by resistance to 
Blasticidin. 
B) Primer pairs used in PCR screens to determine correct double homologous 
recombination are shown.  Also indicated are the expected sizes of the 
DNA bands to be produced by these screens 
A 
 61 
 
 
 
 
Figure 3 – Amplification of RKIP Flanking Regions 
A) Polymerase Chain Reaction amplification of the 3’ RKIP flanking region by 
P2F and P2R primers. 
B) Polymerase Chain Reaction amplification of the 5’ RKIP flanking region by 
P1F and P1R primers. 
 
 
 
 
 
 
A B 
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Figure 4 – Incorporation of Flanking Regions into Plasmid DNA 
A) Miniprep DNA of E. Coli transformed with a ligation mixture of pLPBLP plasmid with 
3’ RKIP flanking region DNA.  Sample 3h shows a larger band of DNA than other 
samples and the control, pLPBLP, alone. 
B) The pLPBLP vector and samples 3g and 3h were single-digested with BamHI to 
confirm a shift in size.  Sample 3h exhibits the shift in size expected by 
incorporation of the 3’ flanking region into pLPBLP. 
C) Miniprep DNA of E. Coli transformed with ligation mixture of PKS- plasmid with 5’ 
RKIP flanking region DNA.  Samples HKd and HKe show larger bands of DNA than 
other samples and the control, PKS-, alone. 
D) The PKS- vector and samples HKc, HKd, and HKe were single-digested with KpnI to 
confirm a shift in size.  Sample HKe exhibits the shift in size expected by 
incorporation of the 5’ flanking region into PKS-. 
E) A pLPBLP control and samples 3g and 3h were double digested with BamHI and 
PstI to check for the presence of a 3’ flanking region insert.  This insert was only 
seen in sample 3h, as expected.  A PKS- control and sample HKd and HKe were 
double digested with HindIII and KpnI to check for the presence of a 5’ flanking 
region insert.  This insert was only seen in sample HKe, as expected. 
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Figure 5 – Completing Targeting Vector Construction 
A) The 5’ RKIP flanking region was cut from the PKS- plasmid (sample HKe 
from Figure 3 C) and used in a ligation mixture with pLPBLP plasmid 
contained the 3’ flanking region of RKIP (sample 3h from Figure 3 A).  E. 
Coli were transformed with this ligated DNA.  Samples 1, 10, 11, and 14 
show larger bands of DNA, of differing sizes, than the control, pLPBLP with 
3’ RKIP flanking region, alone. 
B) The pLPBLP plasmid with 3’ RKIP flanking region as well as samples 1, 10, 
11, and 14 were single-digested with HindIII as well as double-digested 
with HindIII and KpnI.  Samples 1 and 10 are shown to be of the 
appropriate size to indicate insertion of the 5’ RKIP flanking region into the 
pLPBLP plasmid already containing the 3’ RKIP flanking region.  Double 
digests show this 5’ insert to be present.   
C) Sample 10 was selected to be used as the construction vector from this 
point forward.  Double-digestion with BamHI and KpnI is seen to liberate to 
whole targeting fragment from the plasmid backbone. 
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Figure 6 – Problems Encountered in the Making of a Mutant 
A) PCR screens which had appeared to confirm a knockout 
mutant were refuted when a final confirmatory set of PCR 
reactions was performed.  Many unexpected results were 
evident from these screens.  The lack of a band for the 
“knockout” EF/ER screen is suspicious, given the bold bands for 
the wild-type and non-knockout transformed cells.  
Furthermore, the apparent presence of an RKIP coding region 
in the “knockout” for screens CF1/ER and CF2/ER, which 
amplify from the coding region to the exterior of the gene, are 
evidence to conclude that the putative knockout did not 
actually contain a disrupted RKIP gene. 
B) The scenario by which most of these anomalous results can be 
explained is by a 5’ single homologous recombination.  The 
EF/ER screen would likely not work for the mutant, as the size of 
the expected band of the above model would be more than 
six 6 kb.  Furthermore, this model accounts for the presence of 
a both a Bsr cassette as well as coding region, which would 
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Figure 7 – Confirmation of an RKIP Knockout Mutant 
A) PCR screens were used to confirm double homologous recombination of 
the targeting DNA into the AX2 genome.  Screen “i” (using primers EF and 
ER) amplifies the entire RKIP gene and 1.5 kb to each side of the coding 
region.  A shift in size from 3.6 kb to 4.3 kb can be seen in the mutant.  
Screens “ii” and “iii” (using primers EF and IR, and IF and ER) amplify a 
region from the interior of the Blastidicin resistance gene to the flanking 
regions of the RKIP gene.  These bands are present only in the mutant, as 
expected.  Screens “iv” and “v” (using primers EF and CR1, and ER and 
CF2) amplify a region from the interior of the RKIP coding region to the 
flanking regions of the RKIP gene.  These bands are present only in the 
wild-type cells, as expected. 
B) Further confirmation was achieved with Reverse Transcription PCR.  
Wildtype cells show a strong RKIP signal, while putative RKIP knockout 
mutants were shown to exhibit no RKIP signal.   
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Growth of Wildtype and RKIP Knockout Cells in Shaking Suspension 
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Figure 8 – Growth of Wild-Type Cells and Knockout Mutants 
A) Growth curves of wild-type cells and knockout mutants grown in dishes 
as well as in shaking suspension show that knockout cells exhibit lower 
growth rates in both conditions than wild-type cells. 
B) The generation time of knockout cells in a dish is not significantly 
different than wild-type cells in a dish, but is significantly different than 
knockout cells grown in shaking suspension. Furthermore, knockout cells 
grown in shaking suspension exhibit significantly lower growth rates than 
wild-type cells grown in shaking suspension. 
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Figure 9 – Differential Effects of Locostatin on Wild-type and Knockout Cells 
A) Locostatin is added to cells at 20 minutes.  Wild-type and knockout cells 
exhibit similar response time and degree of response to Locostatin when 
they are treated with a 100uM concentration. 
B) Locostatin is added to cells at 20 minutes.  Wild-type cells are far more 
sensitive to 50uM concentrations of Locostatin than knockout cells.  Wild-
type cells exhibit drastically reduced cell speed after only about 5 minutes 
following drug addition, while knockout cells do not experience the same 
degree of inhibition for approximately 90 minutes. 
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Figure 10 - Development on Agar With and Without Locostatin 
A) Wild-type cells developed on agar without drug develop characteristically, 
with fruiting bodies developing after 24 hours. 
B) Knockout cells developed on agar without drug stream normally, but are slow 
to develop into slugs and never develop into fruiting bodies. 
C) Wild-type cells developed on agar with 50uM Locostatin stream normally, but 
form slugs slower than wild-type cells without drug, and at 30 hours exhibit only 
about 25% the number of fruiting bodies seen when cells are developed 
without drug. 
D) Knockout cells developed on agar with 50uM Locostatin do not even begin 
streaming until 24 hours, and streaming occurs in a small proportion of cells.  
Neither slugs nor fruiting bodies ever develop, and cells remain in disorganized 
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